Ending the HIV epidemic: where does Europe stand?
From diagnosis of HIV to successful viral suppression: in a rapid communication published in Eurosurveillance, ECDC and co-authors from Public Health England and The National AIDS Trust summarise the progress towards HIV elimination in 52 countries in Europe and Central Asia. The main issues: diagnosing those who are unaware of their HIV infection and treating them.
Marking European Testing Week: ECDC issues integrated hepatitis and HIV testing Guidance
To mark European Testing Week from 23 to 30 November 2018, ECDC publishes its new Guidance on integrated viral hepatitis and HIV testing.
The benefits of HIV treatment: undetectable means you do not pass on the virus
Since its introduction in the 1990s, the main aim of combination antiretroviral therapy (ART) for HIV has been to halt the progression of the infection, maintaining the health of the HIV-positive person taking treatment. In addition to this, the impact of treatment as prevention has been well described.
1 in 7 people living with HIV in the EU/EEA are not aware of their HIV status
Almost 30 000 newly diagnosed HIV infections were reported by the 31 European Union and European Economic Area (EU/EEA) countries in 2015, according to data published by ECDC and the WHO Regional Office for Europe. This is similar to the observed notification trends in the last decade. One reason for this persistent HIV epidemic: ECDC estimates that currently around 122 000 people living with HIV across the region are unaware of their infection. The estimated time between HIV infection and diagnosis is four years.
Pre-exposure prophylaxis to prevent HIV among MSM in Europe
The results of two clinical studies, PROUD and IPERGAY, suggests that the use of pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) is an effective HIV prevention tool for Europe.
Pre-exposure prophylaxis for HIV in Europe
The use of pre-exposure prophylaxis (PrEP) as an HIV prevention strategy, particularly among men who have sex with men (MSM) as well as other population groups at higher risk of HIV infection, has been receiving more and more attention during 2014. Preliminary results of clinical trials and research studies suggest that it could be an effective HIV prevention tool for Europe.
Treatment as prevention: U.S. CDC introduces clinical guidance on pre-exposure prophylaxis for HIV
The U.S. Centers for Disease Control and Prevention published clinical practice guidelines on pre-exposure prophylaxis (PrEP) for the prevention of HIV. In EU, most countries lack implementation data and formal licensure and guidelines.
Strong leadership, late diagnoses: new ECDC reports show Europe’s response to HIV
ECDC today publishes a first set of reports illustrating how countries have been responding to HIV up till 2012 based on their commitment outlined in the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia. The reports find that, on balance, political leadership in response to HIV is rather strong in the countries of the region.
Investing in HIV response essential to curb on-going HIV transmission in Europe.Archived
New data for 2011 show that more than 121 000 new HIV cases were reported in the WHO European Region, including more than 28 000 new infections in the European Union and the European Economic Area (EU/EEA), indicating an increase for the whole Region compared to the previous year1.